Amgen

Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »

Amgen to build state-of-the-art manufacturing facility in Singapore

Friday, January 18, 2013 02:49 PM

Amgen, a biotech based in Thousand Oaks, Calif., plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.

More... »

BIND, Amgen ink agreement for development of a kinase inhibitor nanomedicine

Wednesday, January 9, 2013 10:13 AM

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has entered into a global collaboration agreement with Amgen, a biotech based in Thousand Oaks, Calif., to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors.

More... »

Labrys Biologics secures $31M financing, acquires antibody for chronic migraine from Pfizer

Friday, January 4, 2013 11:57 AM

Labrys Biologics, a development stage biotechnology company focused on chronic migraines, has completed a $31 million Series A financing from four leading venture capital firms: venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a phase II ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P. James has been appointed president and CEO.

More... »

Amgen to acquire deCODE Genetics

Monday, December 10, 2012 09:40 AM

Amgen, a biotech based in Thousand Oaks, Calif., has entered into a definitive agreement to acquire deCODE Genetics, an Iceland-based company that analyzes the human genome.

More... »

Amgen, KPCB partner to create new spin-out biotech

Friday, October 26, 2012 02:43 PM

Amgen, a biotech based in Thousand Oaks, Calif., and Kleiner Perkins Caufield & Byers (KPCB), a venture capital firm, have created Atara Biotherapeutics, a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology.

More... »

arGEN-X appoints David Lacey to supervisory board

Friday, October 26, 2012 11:12 AM

arGEN-X, a biopharmaceutical company based in The Netherlands and focused on human monoclonal antibodies from its proprietary SIMPLE Antibody platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

More... »

Cytos Biotechnology appoints Itin as CEO

Friday, October 12, 2012 02:29 PM

Cytos Biotechnology, a Swiss biotech company focused on the development of CYT003 in allergic asthma, has appointed Dr. Christian Itin as chief executive officer. The board of directors will propose to the company's shareholders that Itin be elected as member of the board, and it is intended that he will become chairman.

More... »

Spectrum appoints Amgen vet Ken Keller as COO

Thursday, September 13, 2012 08:00 AM

Spectrum Pharmaceuticals, a biotechnology company focused on hematology and oncology, has appointed Ken Keller as executive vice president and COO. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations.

More... »

Y-Prime names Greef as senior business analyst

Thursday, August 30, 2012 02:53 PM

Y-Prime Technologies, an Malvern, Penn.-based eClinical products and life sciences consulting services company, has expanded its international operations in Europe and has named Jeanette Anne Greef as senior business analyst in the U.K. office.

More... »